Finally, Effective Treatments for Tardive Dyskinesia

Topics: Adjunct treatment | AIMS test (Assessment of Involuntary Movement) | Antipsychotics | Assent | Austedo | Deutetrabenazine | Ingrezza | Tardive dyskinesia | Tetrabenazine | Valbenazine | VMAT2 Inhibitors | Xenazine

Antipsychotics, especially first-generation antipsychotics, can cause tardive dyskinesia (TD) or abnormal involuntary movements of different areas of the body. For years, we have dreaded seeing our patients develop TD because there was little we could do about these symptoms. In 2017, the FDA approved two agents to treat TD, valbenazine (Ingrezza) and d

Combination Treatment for Schizophrenia

Topics: Adjunct treatment | Antidepressant | Antipsychotic | Benzodiazepine | CATIE | Combination treatment | Free Articles | Mood stabilizer | Outcomes | Psychopharmacology | Schizoaffective disorder | Schizophrenia | Substance Use Disorder

CHPR: You recently published a study on the use of adjunctive medications in patients with schizophrenia (Stroup TS et al, JAMA Psychiatry 2019;76(5):508–515). Your findings were provocative as you found that adjunctive medications often help improve patients’ outcomes, yet many clinicians avoid polypharmacy because of concern that patients will exp

Does CBT Enhance Pharmacotherapy for Addiction?

Topics: Adjunct treatment | Cognitive Behavioral Therapy | Psychotherapy

REVIEW OF: Ray LA et al, JAMA Network Open 2020;3(6):e208279 Does cognitive behavioral therapy (CBT) provide any extra benefit when added to medication treatment for substance use disorders? It’s not clear. Most notably, in the COMBINE study of comparative treatments for alcohol use disorder (see CATR, Nov/Dec 2019), a combined behavioral intervent